Krsnaa Diagnostics Board Approves Q1 FY27 Results, Recommends ₹2 Dividend, Issues Warrants
Krsnaa Diagnostics approved Q1 FY27 results, reporting consolidated revenue of ₹235.53 crore and PAT of ₹65.51 lakh. Standalone revenue was ₹210.66 crore with PAT of ₹58.20 lakh. The company recommended a ₹2 final dividend and approved issuing 16.21 lakh warrants to promoters at a floor price of ₹565.
The dividend recommendation and the issuance of warrants to promoters are positive but do not represent a significant immediate financial impact on the company's operations.
The company reported its quarterly results, recommended a dividend, and approved a preferential issue of warrants to promoters, all positive developments.
Krsnaa Diagnostics Limited announced the outcome of its Board Meeting held on August 13, 2026. The Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, along with the limited review reports. The company recommended a final dividend of ₹2.00 per equity share for the financial year 2024-25. The record date for dividend payment is September 18, 2026, and book closure will be from September 19 to September 28, 2026.
The Board also approved the Director's report for the financial year 2025-26 and the notice for the 16th Annual General Meeting (AGM) scheduled for September 28, 2026, at 11:00 Hrs. IST, to be held in physical mode.
Furthermore, the company approved the issuance of 16,21,000 share warrants to Mr. Rajendra Mutha and Krsna Diagnostics (Mumbai) Private Limited (Promoter and Promoter Group). The issue price will be determined in the future, based on SEBI ICDR Regulations or ₹565/-, whichever is higher. Each warrant is convertible into one equity share of face value ₹5 within 18 months of allotment.
For the quarter ended June 30, 2026, consolidated revenue from operations stood at ₹235.53 crore, with a profit after tax of ₹65.51 lakh. Standalone revenue from operations was ₹210.66 crore, with a profit after tax of ₹58.20 lakh.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.